Copyright Reports & Markets. All rights reserved.

Global PD-1 Inhibitor Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global PD-1 Inhibitor Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Pembrolizumab
      • 1.4.3 Nivolumab
      • 1.4.4 Atezolizumab
      • 1.4.5 Durvalumab
      • 1.4.6 Avelumab
      • 1.4.7 Other
    • 1.5 Market by Application
      • 1.5.1 Global PD-1 Inhibitor Market Share by Application (2014-2025)
      • 1.5.2 Melanoma
      • 1.5.3 Non-small Cell Lung Cancer (NSCLC)
      • 1.5.4 Urothelial Carcinoma
      • 1.5.5 Classical Hodgkin Lymphoma
      • 1.5.6 Renal Cell Carcinoma
      • 1.5.7 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 PD-1 Inhibitor Market Size
    • 2.2 PD-1 Inhibitor Growth Trends by Regions
      • 2.2.1 PD-1 Inhibitor Market Size by Regions (2014-2025)
      • 2.2.2 PD-1 Inhibitor Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 PD-1 Inhibitor Market Size by by Players
      • 3.1.1 Global PD-1 Inhibitor Revenue by by Players (2014-2019)
      • 3.1.2 Global PD-1 Inhibitor Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global PD-1 Inhibitor Market Concentration Ratio (CR5 and HHI)
    • 3.2 PD-1 Inhibitor Key Players Head office and Area Served
    • 3.3 Key Players PD-1 Inhibitor Product/Solution/Service
    • 3.4 Date of Enter into PD-1 Inhibitor Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global PD-1 Inhibitor Market Size by Type (2014-2019)
    • 4.2 Global PD-1 Inhibitor Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States PD-1 Inhibitor Market Size (2014-2019)
    • 5.2 PD-1 Inhibitor Key Players in United States
    • 5.3 United States PD-1 Inhibitor Market Size by Type
    • 5.4 United States PD-1 Inhibitor Market Size by Application

    6 Europe

    • 6.1 Europe PD-1 Inhibitor Market Size (2014-2019)
    • 6.2 PD-1 Inhibitor Key Players in Europe
    • 6.3 Europe PD-1 Inhibitor Market Size by Type
    • 6.4 Europe PD-1 Inhibitor Market Size by Application

    7 China

    • 7.1 China PD-1 Inhibitor Market Size (2014-2019)
    • 7.2 PD-1 Inhibitor Key Players in China
    • 7.3 China PD-1 Inhibitor Market Size by Type
    • 7.4 China PD-1 Inhibitor Market Size by Application

    8 Japan

    • 8.1 Japan PD-1 Inhibitor Market Size (2014-2019)
    • 8.2 PD-1 Inhibitor Key Players in Japan
    • 8.3 Japan PD-1 Inhibitor Market Size by Type
    • 8.4 Japan PD-1 Inhibitor Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia PD-1 Inhibitor Market Size (2014-2019)
    • 9.2 PD-1 Inhibitor Key Players in Southeast Asia
    • 9.3 Southeast Asia PD-1 Inhibitor Market Size by Type
    • 9.4 Southeast Asia PD-1 Inhibitor Market Size by Application

    10 India

    • 10.1 India PD-1 Inhibitor Market Size (2014-2019)
    • 10.2 PD-1 Inhibitor Key Players in India
    • 10.3 India PD-1 Inhibitor Market Size by Type
    • 10.4 India PD-1 Inhibitor Market Size by Application

    11 Central & South America

    • 11.1 Central & South America PD-1 Inhibitor Market Size (2014-2019)
    • 11.2 PD-1 Inhibitor Key Players in Central & South America
    • 11.3 Central & South America PD-1 Inhibitor Market Size by Type
    • 11.4 Central & South America PD-1 Inhibitor Market Size by Application

    12 International Players Profiles

    • 12.1 Merck
      • 12.1.1 Merck Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 PD-1 Inhibitor Introduction
      • 12.1.4 Merck Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.1.5 Merck Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 PD-1 Inhibitor Introduction
      • 12.2.4 Novartis Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Onxeo
      • 12.3.1 Onxeo Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 PD-1 Inhibitor Introduction
      • 12.3.4 Onxeo Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.3.5 Onxeo Recent Development
    • 12.4 Sumitomo Dainippon Pharma
      • 12.4.1 Sumitomo Dainippon Pharma Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 PD-1 Inhibitor Introduction
      • 12.4.4 Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.4.5 Sumitomo Dainippon Pharma Recent Development
    • 12.5 Taiwan Liposome Company
      • 12.5.1 Taiwan Liposome Company Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 PD-1 Inhibitor Introduction
      • 12.5.4 Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.5.5 Taiwan Liposome Company Recent Development
    • 12.6 Tiziana Life Sciences
      • 12.6.1 Tiziana Life Sciences Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 PD-1 Inhibitor Introduction
      • 12.6.4 Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.6.5 Tiziana Life Sciences Recent Development
    • 12.7 Genentech (Roche)
      • 12.7.1 Genentech (Roche) Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 PD-1 Inhibitor Introduction
      • 12.7.4 Genentech (Roche) Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.7.5 Genentech (Roche) Recent Development
    • 12.8 AstraZeneca
      • 12.8.1 AstraZeneca Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 PD-1 Inhibitor Introduction
      • 12.8.4 AstraZeneca Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.8.5 AstraZeneca Recent Development
    • 12.9 Pfizer
      • 12.9.1 Pfizer Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 PD-1 Inhibitor Introduction
      • 12.9.4 Pfizer Revenue in PD-1 Inhibitor Business (2014-2019)
      • 12.9.5 Pfizer Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global PD-1 Inhibitor market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PD-1 Inhibitor development in United States, Europe and China.

      The key players covered in this study
      Merck
      Novartis
      Onxeo
      Sumitomo Dainippon Pharma
      Taiwan Liposome Company
      Tiziana Life Sciences
      Genentech (Roche)
      AstraZeneca
      Pfizer

      Market segment by Type, the product can be split into
      Pembrolizumab
      Nivolumab
      Atezolizumab
      Durvalumab
      Avelumab
      Other

      Market segment by Application, split into
      Melanoma
      Non-small Cell Lung Cancer (NSCLC)
      Urothelial Carcinoma
      Classical Hodgkin Lymphoma
      Renal Cell Carcinoma
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players.
      To present the PD-1 Inhibitor development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of PD-1 Inhibitor are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now